Eliquis Regulatory Post Marketing Surveillance (rPMS)

Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01885585

Enrollment

100

Registered

2013-06-25

Start date

2014-07-31

Completion date

2015-05-31

Last updated

2016-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Brief summary

The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice

Interventions

DRUGApixaban

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed data release * Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty

Exclusion criteria

* Being treated for an indication not approved for the use of Eliquis® in Korea * Is contraindicated for the use of Eliquis® as described in the Korean label

Design outcomes

Primary

Measure	Time frame
Number of Adverse Events (AEs) and serious AEs	Up to 30 days after last study drug dose

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026